GFP/Luc Reporter Cell Line - SNU-5

The GFP/Luc reporter cell line derived from the SNU-5 cell line has important applications in various areas of biomedical research. Here are a few key uses: Cancer Research: Originally derived from human gastric cancer, the SNU-5 cell line provides a reliable model for studying gastric cancer. The combination of GFP and Luc reporter genes allows researchers to monitor tumor growth, proliferation, and metastasis in real time using fluorescence and luminescence imaging techniques. Drug Screening and Development: This cell line is highly valuable in high-throughput screening (HTS) platforms for identifying potential therapeutic drugs. The GFP and Luc reporter genes facilitate rapid and sensitive detection of changes in cellular activity in response to drug treatment, thereby accelerating the process of drug discovery and development. Gene Expression Studies: Researchers can use the GFP/Luc Reporter Cell Line - SNU-5 to study gene expression regulation. The reporter genes enable visualization and quantification of promoter activity, which helps identify regulatory elements and transcription factors involved in cancer progression. Signal Transduction Pathway Analysis: Dual reporter genes in the cell line can be used to study intracellular signaling pathways. By monitoring changes in GFP and luciferase expression, scientists can dissect molecular mechanisms and pathways affected by genetic or pharmacological interventions. In Vivo Imaging: The GFP/Luc Reporter Cell Line - SNU-5 can be used for in vivo imaging studies in animal models. The ability to non-invasively track and quantify tumor growth and metastasis in vivo enhances the understanding of cancer biology and the evaluation of therapeutic strategies. Cell Migration and Invasion Assays: Researchers can use this cell line to study the mechanisms underlying cancer cell migration and invasion. The GFP component is particularly useful in visualizing and quantifying cell motility, providing insights into metastatic behavior and potential targets for anti-metastatic therapies.